lin Med (Lond). 2021;21(3):170-173. doi:10.7861/clinmed.2021-0257

Luger, T, et al. Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey.Dermatol Ther (Heidelb). 2022;12:949–969.https://doi.org/10.1007/s13555-022-00700-6

Oisín S, et al. 545 - Prevalence of moderate and severe atopic dermatitis in Ireland: a cross-sectional, real-world study of a secondary care population.BJD. 2024;190(S2):ii43–ii44.https://doi.org/10.1093/bjd/ljad498.045

Ständer S, et al. Efficacy and Safety of Nemolizumab in Patients with Moderate-to-Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Controlled Phase 3 Trial.JAMA Derm.2024;161(2):147-156. doi: 10.1001/jamadermatol.2024.4796

Kwatra SG, et al. Placebo-controlled phase III trial of nemolizumab in patients with prurigo nodularis.N Engl J Med. 2023;389:1579-89. doi: 10.1056/NEJMoa2301333

Huang AH, et al. Prurigo n
=*=*=*=*=*=
当前为第14/16页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页